WHO to List Exchange Programs in Cancer Ed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) is putting together a list of exchange programs in cancer education, (eg, exchange of students, residents, or faculty), involving a European or US center and a corresponding center in Asia, Africa, or Latin America.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) is putting together a list of exchange programs in cancer education, (eg, exchange of students, residents, or faculty), involving a European or US center and a corresponding center in Asia, Africa, or Latin America.

The INCE is sponsoring a symposium on such exchange programs on November 4-7, 1998, in Portland, Oregon, and is soliciting descriptions of such activities, comments, and ideas for future use, as well as abstracts of papers.

Physicians or institutions may contact Charles D. Sherman, Jr, MD, Highland Hospital, 1000 South Avenue, Rochester, NY 14620.

Articles in this issue
Intensive Effort Required to Develop a Breast Cancer Risk Assessment Clinic
NCI Readies Its Cancer Genetics Network for Collaborative Studies
Payer Relationships Key to Transplant Revenues
Taking Family Cancer History May Release Emotions
Ovarian Cortical Tissue Is Cryopreserved for Future Fertility
Advice Offered for Daughters of Women With Breast Cancer
WHO to List Exchange Programs in Cancer Ed
Women’s Groups Ask Congress for Global Tobacco Controls
Brain Tumor Patients Urged to ‘Seize Control’ of Their Seizures
UCSF Breaks Ground for Its New Clinical Cancer Building
Preventive Effects of Tamoxifen Vary With HER2 Level
NIH Expert Dispels Myths About Genetic Counseling
Advanced Colorectal Cancer Patients May Prefer Raltitrexed
FDG-PET Finds Residual, Recurrent Hodgkin's Disease
Ceprate Gets FDA Nod for Peripheral Blood Stem Cell Selection
Recent Videos
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.